methyl-inosine-monophosphate and HIV-Infections

methyl-inosine-monophosphate has been researched along with HIV-Infections* in 4 studies

Reviews

1 review(s) available for methyl-inosine-monophosphate and HIV-Infections

ArticleYear
Recent thoughts on the immunotherapy of infectious diseases including HIV infection.
    Advances in experimental medicine and biology, 1992, Volume: 319

    Topics: Adjuvants, Immunologic; AIDS-Related Complex; Animals; Antiviral Agents; HIV Infections; Humans; Immunotherapy; Infections; Inosine Monophosphate; T-Lymphocytes

1992

Other Studies

3 other study(ies) available for methyl-inosine-monophosphate and HIV-Infections

ArticleYear
Methyl inosine monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants.
    International journal of immunopharmacology, 1995, Volume: 17, Issue:9

    Methyl inosine monophosphate (MIMP) augments preferentially the in vitro responses of human and murine lymphocytes to a T-cell mitogen such as phytohemagglutinin (PHA) and inconsistently to a B-cell mitogen such as pokeweed or lipopolysaccharide (LPS). In a normal interleukin-2-dependent cell line (CTLL), MIMP showed little or no effect on IL-2 action; however, in a murine CTLL line exhibiting impaired responses to IL-2, MIMP stimulated thymidine incorporation and restored the response to IL-2. MIMP augments the PHA responses of both CD4+ and CD8+ human peripheral blood T-cells. The effect of MIMP to augment the PHA response of human lymphocytes is paralleled by the parent molecule, IMP. MIMP, but not IMP, is resistant to hydrolysis by 5'nucleotidase; thus, MIMP appears to be a protected analogue of IMP which is capable of in vivo action. MIMP (100 micrograms/ml) augments the PHA responses of 15 to 24 elderly humans. MIMP also augments the PHA responses of eight HIV-infected pre-AIDS patients but not of eight AIDS patients. When PHA responses of human lymphocytes are suppressed in vitro by an HIV-derived immunosuppressive peptide, interferon alpha, or prostaglandin PGE2, MIMP (0.1-100 micrograms/ml) progressively restores the depressed response; however, when the suppression is severe (greater than 50%), MIMP cannot restore the response. These data indicate that MIMP potentiates normal T-lymphocyte mitogen responses and restores those impaired by a variety of inflammatory and immunosuppressive influences.

    Topics: Animals; Antiviral Agents; Cells, Cultured; Dinoprostone; Dose-Response Relationship, Drug; HIV Infections; Humans; Immunosuppressive Agents; Inosine Monophosphate; Interferon-alpha; Mice; Mitogens; Spleen; T-Lymphocytes

1995
Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection.
    International journal of immunopharmacology, 1992, Volume: 14, Issue:4

    MIMP is a new thymomimetic purine under development for immunorestorative therapy. Lymphocytes were obtained from eight patients with acquired immunodeficiency disease (AIDS), eight with symptomatic pre-AIDS (ARC), and 22 normal controls and were stimulated in vitro with phytohemagglutinin (PHA). AIDS patients (mean CD4 counts of 40) showed PHA responses less than 10% of control while ARC patients (mean CD4 counts of 544) showed responses approximately 50% of the control responses. MIMP (0.1, 1, 10 and 100 micrograms/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of ARC patients was significant and their maximal responses approached control levels. The effect of 1 micrograms/ml MIMP was comparable with that observed with indomethacin (10(-6) M) and interleukin-2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP restored the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression.

    Topics: Adjuvants, Immunologic; Adult; Animals; Female; Friend murine leukemia virus; HIV Infections; Humans; In Vitro Techniques; Indomethacin; Inosine Monophosphate; Interleukin-2; Leukemia, Experimental; Lymphocytes; Mice; Mice, Inbred BALB C; Middle Aged; Phytohemagglutinins

1992
Methyl inosine monophosphate (MIMP), a new purine immunomodulator for HIV infection.
    International journal of immunopharmacology, 1991, Volume: 13 Suppl 1

    Prior work has documented the thymomimetic and immunotherapeutic activity of purine molecules related in structure to inosine. Synthesis of a series of new structures has yielded a stable methylated form of IMP resistant to hydrolysis by 5' nucleotidase. With both human peripheral blood lymphocytes and murines splenocytes, Methyl Inosine Monophosphate (MIMP) augments proliferative responses to T-cell mitogens like phytohemagglutinin (PHA), but less so, or not at all, to B-cell mitogens like pokeweed or endotoxin (LPS). MIMP does not directly stimulate lymphocytes alone in the absence of mitogen. The optimal effects of MIMP parallel the optimal effects of PHA. The magnitude of the effect is greater and more consistent than with other purine immunomodulators. MIMP is non-toxic in vitro and in vivo and is orally active in mice. Significant effects are observed as low as 0.1 and 1 micrograms/ml in vitro and 0.1 or 1 mg/kg in vivo. MIMP is a candidate third generation purine under development for immunotherapeutic purposes.

    Topics: Adjuvants, Immunologic; Animals; HIV Infections; Humans; Inosine Monophosphate; Lymphocyte Activation; Mice; Mice, Inbred BALB C; T-Lymphocytes

1991